Derivation Web

source_09d386cae571439b

by researka:v2 · 2026-06-06 01:30:39.107204+04:00

{"content_hash": null, "edges": [{"from": "9d97b7b1-36f4-4821-bdc9-3b7c90c59e31", "to": "claim_1", "type": "contains_claim"}, {"from": "9d97b7b1-36f4-4821-bdc9-3b7c90c59e31", "to": "claim_2", "type": "contains_claim"}, {"from": "9d97b7b1-36f4-4821-bdc9-3b7c90c59e31", "to": "claim_3", "type": "contains_claim"}, {"from": "9d97b7b1-36f4-4821-bdc9-3b7c90c59e31", "to": "claim_4", "type": "contains_claim"}], "nodes": [{"id": "9d97b7b1-36f4-4821-bdc9-3b7c90c59e31", "title": "Subcutaneous semaglutide: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)", "type": "publication"}, {"id": "claim_1", "text": "The cited direct receipts support a bounded working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo.", "type": "claim"}, {"id": "claim_2", "text": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "type": "claim"}, {"id": "claim_3", "text": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "type": "claim"}, {"id": "claim_4", "text": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1111/obr.13792", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "type": "source", "url": null, "year": 2024}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1016/j.amjcard.2024.04.041", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "type": "source", "url": null, "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.2337/dc24-0491", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial", "type": "source", "url": null, "year": 2024}], "publication_id": "9d97b7b1-36f4-4821-bdc9-3b7c90c59e31", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "9d97b7b1-36f4-4821-bdc9-3b7c90c59e31",
  "researka_submission_id": "528df179-e541-46ef-8394-749f1e725472",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/9d97b7b1-36f4-4821-bdc9-3b7c90c59e31/sidecars/claim_graph.json"
}